New drug for chronic obstructive pulmonary disease, tozorakimab, successfully completed two clinical trials.

The preliminary positive results of the OBERON and TITANIA Phase III trials targeting interleukin-33 with AstraZeneca's monoclonal antibody Tozorakimab in patients with chronic obstructive pulmonary disease (COPD) showed that, compared to the placebo group, Tozorakimab reduced the rate of severe acute exacerbations per year in the primary study population as well as the overall population. Tozorakimab demonstrated good overall tolerability and safety.